Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | AURKA | O14965 | 1/20 | 0.31 |
| ▸ | CSF1R | P07333 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | LTK | P29376 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | CLK2 | P49760 | 1/20 | 0.31 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.31 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.31 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22100078 | 0.80 | POLB (0.30) | POLBSMN1; SMN2 | |
| SCHEMBL5760635 | 0.72 | MAPK1 (0.36) | POLB | |
| SCHEMBL5758085 | 0.68 | SMN1; SMN2 (0.41) | ALDH1A1LMNAPOLBSMN1; SMN2 | |
| SCHEMBL5755437 | 0.65 | RECQL (0.47) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL5757737 | 0.64 | SRC (0.34) | ALDH1A1LMNA | |
| SCHEMBL2105684 | 0.64 | AOC3 (0.38) | AOC3 | |
| SCHEMBL12921936 | 0.63 | LMNA (0.43) | ALDH1A1LMNAAURKACSF1RRET | |
| SCHEMBL9978660 | 0.61 | MAPK1 (0.37) | ALDH1A1LMNAPOLB | |
| SCHEMBL5754483 | 0.60 | MAPT (0.40) | LMNA | |
| SCHEMBL21298820 | 0.60 | LMNA (0.32) | LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1303499-B1 | TETRAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-07-12 | — | — | EP | claimed |
| EP-1303499-A1 | TETRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | claimed |
| US-6399641-B1 | FOR THERAPY AND PROPHYLAXIS OF PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND RESTRICTED BRAIN FUNCTION CAUSED BY BYPASS OPERATIONS OR TRANSPLANTS, POOR BLOOD SUPPLY TO THE BRAIN, SPINAL CORD INJURIES ETC. | HOFFMANN-LA ROCHE INC. | 2002-06-04 | — | — | US | claimed |
| US-20020022648-A1 | Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists | HOFFMANN-LA ROCHE INC. | 2002-02-21 | — | — | US | claimed |
| WO-2002006254-A1 | TETRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | claimed |
| CN-116917279-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-1303499-B1 | TETRAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-07-12 | — | — | EP | disclosed |
| EP-1303499-A1 | TETRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-23 | — | — | EP | disclosed |
| US-6399641-B1 | FOR THERAPY AND PROPHYLAXIS OF PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND RESTRICTED BRAIN FUNCTION CAUSED BY BYPASS OPERATIONS OR TRANSPLANTS, POOR BLOOD SUPPLY TO THE BRAIN, SPINAL CORD INJURIES ETC. | HOFFMANN-LA ROCHE INC. | 2002-06-04 | — | — | US | disclosed |
| US-20020022648-A1 | Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists | HOFFMANN-LA ROCHE INC. | 2002-02-21 | — | — | US | disclosed |
| WO-2002006254-A1 | TETRAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022648-A1 | Novel 2H-tetrazole-amide compounds with therapeutic activity as metabotropic glutamate receptor agonists | GRM1, GRM3, GRM2 | ALDH1A1 2423/4885LMNA 4874/4885AURKA 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.